Reports the development of a continuous manufacturing process for a key compound, indicating improved efficiency.
This paper outlines the development of a continuous manufacturing process for producing the key compound tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate. A 3-step process, performed in batch, had been utilized to deliver significant quantities of the target compound. By employing the same bond-forming chemistry, we designed, optimized, and scaled a flow process that delivers multikilogram quantities of tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate with equivalent quality. This new process offers several superior metrics, including lower PMI and reduced cycle time.
No takes yet. Share an insight, caveat, or question.
Baldwin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: